TOP2A and leiomyoma: Two members of the retinoblastoma pathway, TOP2A and CDK1, were further shown as potential diagnostic biomarkers to distinguish leiomyomas from leiomyosarcomas and as prognostic tools in leiomyosarcoma patients.